USPTO serial 97007212
AIMS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MORENO, PAUL A
- Law office
- TMEG LAW OFFICE 103 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with AIMS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Carey Kulp
Carey Kulp Volpe Koenig30 South 17th StreetSuite 1800Philadelphia, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and compounds for use in immune modulation, oncology, infectious diseases; pharmaceutical preparations for the treatment or prevention of immune-mediated diseases, Crohn's disease, multiple sclerosis, viral infections, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immuno-compromised patient; dietetic substances for medical purposes, namely, nutritional, vitamin and mineral supplements | ACTIVE | — |
| 041 | Educational services, namely, conducting classes, seminars, conferences, and workshops and distributing printed course materials in conjunction therewith; providing on-line journals, namely, blogs in the medical, pharmaceutical and health fields | ACTIVE | — |
| 042 | Pharmaceutical and therapeutics research and development services for systemically delivered, locally active immune restorative conjugates, small molecules and peptides; research and development of systemically delivered, locally active immune restorative conjugates, small molecules and peptides in the pharmaceutical, therapeutics and biotechnology fields; research and product development of systemically delivered, locally active immune restorative conjugates, small molecules and peptides in the field of human therapeutics; research services using a platform of biological research tools and techniques for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases with systemically delivered, locally active immune restorative conjugates, small molecules and peptides; pharmaceutical product development of systemically delivered, locally active immune restorative conjugates, small molecules and peptides | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 27, 2022 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 27, 2022 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 27, 2022 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 11, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 6, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 18, 2022 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 15, 2022 | ALIE | ASSIGNED TO LIE | — |
| Jan 12, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 14, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 4, 2021 | NWAP | NEW APPLICATION ENTERED | — |